Generic vs Brand Changes

In some instances the multisource brand name drug is required over its generic equivalents, because the branded drug is less costly than its generic counterpart. This happens most often in cases of newly released generics. When manufacturer rebates are taken into consideration, the brand name drug has a lower net cost to the State.

Effective Tuesday, November 1, 2016, MMPP will cover brands Cubicin® Injection, E.E.S Granules and Eryped Suspension over their generic counterparts (daptomycin injection and erythromycin ethylsuccinate 200mg/5ml granules and suspension). Claims for these products must be submitted with DAW 6 and will be priced appropriately. Claims with any other DAW code will reject. A DHMH Medwatch form will not be required.

If any problems are encountered during the on-line claim adjudication, contact Xerox 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance). All Advisories are available online on DHMH’s web link at:
https://mmcp.dhmh.maryland.gov/pap/pages/Provider-Advisories.aspx